Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Pump-Delivered Parkinson's drug shows promise in Long-Term safety trial

NCT ID NCT04750226

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the safety of a new drug, ABBV-951, given as a continuous 24-hour infusion under the skin for people with advanced Parkinson's disease. 118 adults who had completed earlier studies took part. The goal was to see if the drug is safe and tolerable over 96 weeks, while also checking if it helps control symptoms like tremors and stiffness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ABBV-951 (a combination of levodopa and carbidopa given as a continuous infusion under the skin)
What this could lead to
If successful, this could provide a more steady and convenient way to deliver Parkinson's medication, potentially reducing the 'off' times when symptoms return between doses.
What could go wrong
This is an extension study focused on safety, not proof of effectiveness. Side effects from the infusion site or the drug itself may occur, and the treatment requires wearing a pump continuously.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

118 people

The number who actually took part.

Started

Feb 2021

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Completion of the parent study, Study M15-736 or Study M20-339. Exclusion Criteria: \- Participant considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease (PD)

Contacts and locations

Locations

  • Alpine Clinical Research Center /ID# 218461

    Boulder, Colorado, 80301-1880, United States

  • Baylor College of Medicine /ID# 217728

    Houston, Texas, 77030, United States

  • CenExel Rocky Mountain Clinical Research, LLC /ID# 217731

    Englewood, Colorado, 80113-2736, United States

  • Coastal Neurology /ID# 222893

    Port Royal, South Carolina, 29935-2029, United States

  • Denver Neurological Research, LLC /ID# 217811

    Denver, Colorado, 80210-7009, United States

  • Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 218607

    West Hollywood, California, 90048, United States

  • Duplicate_Medical College of Wisconsin /ID# 217721

    Milwaukee, Wisconsin, 53226-3522, United States

  • Georgetown University Hospital /ID# 218599

    Washington D.C., District of Columbia, 20007, United States

  • Global Neurosciences Institute /ID# 218472

    Lawrenceville, New Jersey, 08648-2300, United States

  • Gold coast University Hospital /ID# 221694

    Southport, Queensland, 4215, Australia

  • Houston Pulmonary Sleep and Allergy Associates /ID# 218473

    Cypress, Texas, 77429, United States

  • Inland Northwest Research /ID# 222520

    Spokane, Washington, 99202-1342, United States

  • KCA Neurology - Franklin /ID# 222811

    Franklin, Tennessee, 37067-5914, United States

  • Legacy Medical Group - Neurology /ID# 217804

    Portland, Oregon, 97232-2003, United States

  • Liverpool Hospital /ID# 221693

    Liverpool, New South Wales, 2170, Australia

  • Loma Linda University Medical /ID# 217724

    Loma Linda, California, 92354, United States

  • M3 Wake Research - Raleigh /ID# 218482

    Raleigh, North Carolina, 27612-8106, United States

  • Movement Disorders Center of Arizona /ID# 218471

    Scottsdale, Arizona, 85258-4582, United States

  • Muhammad Ali Parkinson Center /ID# 218609

    Phoenix, Arizona, 85013-4407, United States

  • Neuro Pain Research Center /ID# 217720

    Fresno, California, 93710, United States

  • Neurological Associates - Forest Ave /ID# 218458

    Richmond, Virginia, 23229-4913, United States

  • Neurology Associates Ormond Beach /ID# 217800

    Ormond Beach, Florida, 32174, United States

  • Northwell Health /ID# 218600

    Lake Success, New York, 11042, United States

  • Parkinson's Disease Treatment Center of Southwest Florida /ID# 222679

    Port Charlotte, Florida, 33980, United States

  • Premiere Research Institute - Palm Beach /ID# 218743

    West Palm Beach, Florida, 33407-3209, United States

  • Prisma Health-Upstate /ID# 217803

    Greenville, South Carolina, 29615, United States

  • Renstar Medical Research /ID# 217837

    Ocala, Florida, 34470, United States

  • Royal Adelaide Hospital /ID# 218417

    Adelaide, South Australia, 5000, Australia

  • Rush University Medical Center /ID# 217807

    Chicago, Illinois, 60612, United States

  • SC3 Research Group - Pasadena /ID# 223018

    Pasadena, California, 91105-3149, United States

  • St Elizabeth's Medical Center - Brighton /ID# 223082

    Brighton, Massachusetts, 02135-2907, United States

  • St. David's Healthcare Partnership, L.P., LLP /ID# 248148

    Austin, Texas, 78701-4082, United States

  • St. Lukes Hosp. of Kansas City /ID# 218604

    Kansas City, Missouri, 64111, United States

  • Texas Movement Disorder Specialists /ID# 218610

    Georgetown, Texas, 78628-4126, United States

  • The Movement Disorder Clinic of Oklahoma /ID# 218580

    Tulsa, Oklahoma, 74136-6378, United States

  • The Orthopedic Foundation /ID# 218608

    New Albany, Ohio, 43054-8167, United States

  • The Royal Melbourne Hospital /ID# 218419

    Parkville, Victoria, 3050, Australia

  • Thomas Jefferson University Hospital /ID# 218594

    Philadelphia, Pennsylvania, 19107, United States

  • University of Alabama at Birmingham - Main /ID# 217814

    Birmingham, Alabama, 35233, United States

  • University of California, Los Angeles /ID# 218460

    Los Angeles, California, 90095, United States

  • University of California, San /ID# 218595

    San Diego, California, 92037, United States

  • University of Chicago Medical Center /ID# 218611

    Chicago, Illinois, 60637, United States

  • University of Colorado Hospital /ID# 218486

    Aurora, Colorado, 80045, United States

  • University of Pennsylvania /ID# 218605

    Philadelphia, Pennsylvania, 19104-5502, United States

  • University of South Florida- Neuroscience Institute /ID# 218481

    Tampa, Florida, 33613, United States

  • University of Utah Health Care /ID# 218597

    Salt Lake City, Utah, 84132, United States

  • Usa Mitchell Cancer Institute /ID# 218467

    Mobile, Alabama, 36604, United States

  • Vanderbilt University Medical Center /ID# 217722

    Nashville, Tennessee, 37232-0011, United States

  • Visionary Investigators Network - Miami /ID# 217726

    Miami, Florida, 33176-2148, United States

  • Washington University-School of Medicine /ID# 217723

    St Louis, Missouri, 63110, United States

  • Westmead Hospital /ID# 218418

    Westmead, New South Wales, 2145, Australia

  • Xenoscience, Inc /ID# 222515

    Phoenix, Arizona, 85004, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.